This study is designed to assess the efficacy, safety and tolerability of ixmyelocel-T
compared to placebo (vehicle control) when administered via transendocardial catheter-based
injections to patients with end stage heart failure due to IDCM, who have no reasonable
revascularization options (either surgical or percutaneous interventional) likely to provide
clinical benefit.